ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "longitudinal studies"

  • Abstract Number: 1784 • ACR Convergence 2022

    Gait Alterations Associated with Worsening Physical Function over 2 Years: A Machine-learning Approach in the Multicenter Osteoarthritis (MOST) Study

    Kathryn Bacon1, David Felson1, S. Reza Jafarzadeh2, Vijaya Kolachalama2, Jeffrey Hausdorff3, Eran Gazit4, Joshua Stefanik5, Patrick Corrigan6, Neil Segal7, Cora E. Lewis8, Michael Nevitt9 and Deepak Kumar1, 1Boston University, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Tel Aviv University, Tel Aviv, Israel, 4Tel Aviv Suarasky Medical Center, Tel Aviv, Israel, 5Northeastern University, Boston, MA, 6Saint Louis University, St. Louis, MO, 7University of Kansas, Kansas City, KS, 8University of Alabama at Birmingham, Birmingham, AL, 9University of California at San Francisco, Orinda, CA

    Background/Purpose: Altered gait is related to pathogenesis of knee osteoarthritis (OA). For people with knee OA, in addition to pain, declines in physical function are…
  • Abstract Number: 0342 • ACR Convergence 2022

    Multi-Parametric Interrogation of the Systemic Lupus Erythematosus (SLE) Immunome Reveals Multiple Derangements

    Katherine Nay Yaung1, Joo Guan Yeo2, Hui Nee Annie Law3, Martin Wasser4, Thaschawee Arkachaisri5, Julian Thumboo3, Andrea Low3 and Salvatore Albani4, 1Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore; Duke-NUS Medical School, Singapore, Singapore, 2KK Hospital, Singapore; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore, 3Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 4Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore, Singapore, 5KK Women's and Children's Hospital, SingHealth, Singapore, Singapore

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, systemic autoimmune disease that interferes with the balance between regulation and immunity, resulting in immune system dysfunction.…
  • Abstract Number: 1842 • ACR Convergence 2022

    Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry

    Jasmin B. Kuemmerle-Deschner1, Joerg Henes2, Birgit Kortus-Goetze3, Tilmann Kallinich4, Prasad T. Oommen5, Juergen Rech6, Tobias Krickau7, Frank Weller-Heinemann8, Gerd Horneff9, Ales Janda10, Ivan Foeldvari11, Catharina Schuetz12, Frank Dressler13, Michael Borte14, Markus Hufnagel15, Florian Meier16, Michael Fiene17, Julia Weber-Arden18 and Norbert Blank19, 1Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, 2Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 3Division of Nephrology, University of Marburg, Marburg, Germany, 4Charité - Universitätsmedizin Berlin, Nuremberg, Germany, 5Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 6University Clinic Erlangen, Erlangen, Germany, 7Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, 8Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, 9Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 10Department of Pediatrics, University Hospital Ulm, Ulm, Germany, 11Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 12Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, 13Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, 14ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, 15Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, 16Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, 17Rheumatology Center Greifswald, Greifswald, Germany, 18Novartis Pharma GmbH, Nuernberg, Germany, 19Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    Background/Purpose: Treatment of autoinflammatory periodic syndromes with the interleukin-1β inhibitor canakinumab (CAN) has been shown to be safe and effective in clinical trials and in…
  • Abstract Number: 0362 • ACR Convergence 2022

    The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Renal Responses in Lupus Nephritis

    Hermine I. Brunner1, Catharina Lindholm2, Ellen Cody1, Prasad Devarajan1, Bin Huang1, Dominic Sinibaldi3, Madhu Ramaswamy3, Jacob Knagenhjelm4, Tingting Qiu1, Frederick Jones5, Philip Brohawn3, Raj Tummala3 and Wendy White3, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2AstraZeneca, Gothenburg, Sweden, 3AstraZeneca, Gaithersburg, MD, 4AstraZeneca, Gateborg, Sweden, 5AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: LN confers poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We previously showed that…
  • Abstract Number: 1933 • ACR Convergence 2022

    PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results

    Gina Montealegre Sanchez1, Roberta DeBiasi2, Lauren Arrigoni2, Kevin Rubenstein3, Jason Liang4, James Bost2, Marcin Gierdalski2, Max Wolff3, Mallory Barrix2, Maureen Edu2, Saira Huq2, Shera Weyers3, Patricia Bandettini5, Dorothy Bulas2, Tom Burklow6, Marcus Chen5, Sanchita Das6, Robin Dewar3, Joseph Fontana5, Ashraf Harahsheh2, Linda Herbert2, Anastassios Koumbourlis2, Andrew Lipton5, Laura Olivieri2, Dinesh Pillai2, Vandana Sachdev5, Craig Sable2, Audrey Thurm7, Evrim Turkbey6, Alexandra Yonts2, Jonathan Zember2, Eric Vilain2, Meghan Delaney2, Luigi Notarangelo4, David Wessel8 and Karyl Barron4, 1NIAID/NIH, Garrett Park, MD, 2Children's National Hospital, Washington, DC, 3Frederick National Laboratory for Cancer Research, Frederick, MD, 4NIAID/NIH, Bethesda, MD, 5NHLBI/NIH, Bethesda, MD, 6CC/NIH, Bethesda, MD, 7NIMH/NIH, Bethesda, MD, 8Children's National Hospital, Washington, MD

    Background/Purpose: The long-term complications of SARS-CoV-2 and MIS-C in children are unknown. PECOS, a joint study at the National Institutes of Health (NIH) Clinical Center…
  • Abstract Number: 0532 • ACR Convergence 2022

    Women with Early Rheumatoid Arthritis Less Likely to Achieve Rapid and Sustainable Remission: Results from the Canadian Early Arthritis Cohort Study

    orit schieir1, Susan Bartlett2, Marie-France Valois1, Glen Hazlewood3, Louis Bessette4, Gilles Boire5, Carol Hitchon6, Edward Keystone7, Janet Pope8, diane tin9, Carter Thorne10, Vivian Bykerk11 and Canadian Early Arthritis Cohort (CATCH) Investigators12, 1McGill University, Montréal, QC, Canada, 2McGill University, Montreal, QC, Canada, 3University of Calgary, Calgary, AB, Canada, 4Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 5Universite de Sherbrooke, Sherbrooke, QC, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8University of Western Ontario, London, ON, Canada, 9Centre of Arthritis Excellence (CArE), Newmarket, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Hospital for Special Surgery, New York, NY, 12The Canadian Early Arthritis Cohort (CATCH), Bowmanville, ON, Canada

    Background/Purpose: Historical and established RA cohorts have reported sex disparities in remission outcomes favoring male patients. The objective of the present study was to compare…
  • Abstract Number: 2018 • ACR Convergence 2022

    Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome

    Liseth de Wolff1, Suzanne Arends2, Alja Stel3, Greetje van Zuiden3, Jolien van Nimwegen2, Arjan Vissink4, Frans Kroese2, Gwenny Verstappen2 and Hendrika Bootsma2, 1UMCG, Zwolle, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands, 3University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, 4University Medical Center Groningen, University of Groningen, Groningen, Netherlands

    Background/Purpose: The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is often used as primary endpoint in randomised clinical trials (RCTs) in patients with primary Sjögren's…
  • Abstract Number: 0756 • ACR Convergence 2022

    Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions

    Alana Bruce1, Georgina V Long2, Alexander M Menzies2, Brian Fernandes3 and Fredrick Joshua4, 1Macquarie University, Balaclava, Victoria, Australia, 2Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia, 3Royal Prince Alfred Hospital, Sydney, Australia, 4Macquarie University, Integrated Specialist Medical Care, Sydney, Australia

    Background/Purpose: To estimate the frequency of rheumatic toxicities of immune checkpoint inhibitors (ICI) presenting as de novo or exacerbations of pre-existing rheumatic disease in patients…
  • Abstract Number: 2025 • ACR Convergence 2022

    Natural History of Sjögren’s Disease from the National Institutes of Health Cohort

    Brandon Law1, Margaret Beach2, Eileen Pelayo2, Ilias Alevizos2, Zohreh Khavandgar2, Blake Warner2 and Alan Baer1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2National Institutes of Health, Bethesda, MD

    Background/Purpose: The objectives of this study were to assess the natural history of Sjögren's disease (SjD) over an interval reaching up to 32 years among…
  • Abstract Number: 0812 • ACR Convergence 2022

    3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry

    Jasmin B. Kuemmerle-Deschner1, Birgit Kortus-Goetze2, Prasad T. Oommen3, Ales Janda4, Juergen Rech5, Catharina Schuetz6, Tilmann Kallinich7, Frank Weller-Heinemann8, Gerd Horneff9, Ivan Foeldvari10, Florian Meier11, Michael Borte12, Tobias Krickau13, Julia Weber-Arden14 and Norbert Blank15, 1Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, 2Division of Nephrology, University of Marburg, Marburg, Germany, 3Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 4Department of Pediatrics, University Hospital Ulm, Ulm, Germany, 5University Clinic Erlangen, Erlangen, Germany, 6Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, 7Charité - Universitätsmedizin Berlin, Nuremberg, Germany, 8Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, 9Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 10Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 11Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, 12ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, 13Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, 14Novartis Pharma GmbH, Nuernberg, Germany, 15Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    Background/Purpose: Cryopyrin-associated periodic syndromes (CAPS) are monogenic autoinflammatory diseases with severe systemic inflammation. The IL-1β inhibitor canakinumab (CAN) leads to a rapid remission of CAPS…
  • Abstract Number: 2069 • ACR Convergence 2022

    Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort

    Aarabi Thayaparan1, Patricia Katz2, Mitra Moazzami3, Dennisse Bonilla1, Lisa Engel4, Jiandong Su1, Pooneh Akhavan5, Sherief Marzouk6, Nathalie Rozenbojm7, Nicole Anderson1, Oshrat Tayer-Shifman8, Dorcas Beaton9 and Zahi Touma1, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2UCSF, San Rafael, CA, 3George Washington University, Washington, DC, 4University of Manitoba, Winnipeg, MB, Canada, 5Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 6University Health Network, University of Toronto, Toronto, ON, Canada, 7University Health Network, Toronto, ON, Canada, 8Meir Medical Center, Kfar Saba, Israel, 9Institute for Work & Health, Toronto, ON, Canada

    Background/Purpose: Clinicians should include Patient-Reported Outcome (PRO) measures in the assessment of lupus patients, as they are crucial in providing patient-centred care. The Patient Reported…
  • Abstract Number: 0813 • ACR Convergence 2022

    Canakinumab in Patients with Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) – Long-term Efficacy and Safety Data from a RELIANCE Registry Interim Analysis

    Norbert Blank1, Catharina Schuetz2, Joerg Henes3, Tilmann Kallinich4, Prasad T. Oommen5, Michael Borte6, Markus Hufnagel7, Ales Janda8, Julia Weber-Arden9 and Jasmin B. Kuemmerle-Deschner10, 1Rheumatology, University Hospital Heidelberg, Heidelberg, Germany, 2Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, 3Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 4Charité - Universitätsmedizin Berlin, Nuremberg, Germany, 5Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 6ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, 7Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, 8Department of Pediatrics, University Hospital Ulm, Ulm, Germany, 9Novartis Pharma GmbH, Nuernberg, Germany, 10Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany

    Background/Purpose: TRAPS is a rare hereditary autoinflammatory disease characterized by periodic fever and severe systemic and organ inflammation. Successful treatment was achieved with the interleukin-1β…
  • Abstract Number: 2100 • ACR Convergence 2022

    Employment Trajectory of Canadian Young Adults with Systemic Lupus Erythematosus

    Lily Lim1, Menelaos Konstanidis2, Zahi Touma3, Diane Lacaille4, Umut Oguzoglu1, Christine Peschken1, Nicole Anderson3, Ramandeep Kaur1 and Eleanor Pullenayegum2, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Toronto, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 4Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Young adulthood (18-30 years) is a time of many changes. Young adults finish school, enter the labour force, and maybe start their own families.…
  • Abstract Number: 0937 • ACR Convergence 2022

    Conventional Synthetic DMARDs Re-treatment for Rheumatoid Arthritis Flare During Drug-free Follow-up: Rate, Dynamics and Quality of Clinical Response

    Emanuele Bozzalla Cassione1, Iolanda Mazzucchelli2, Terenzj Luvaro2, Blerina Xoxi2, Ludovico De Stefano2, Garifallia Sakellariou2, Silvia Grignaschi2, Mehrad Mansoubi2, Serena Bugatti2, Carlomaurizio Montecucco2 and Antonio Manzo3, 1University of Pavia, IRCCS Policlinico San Matteo Foundation, Milano, Milan, Italy, 2University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Pavia, Italy, 3IRCCS Policlinico San Matteo Foundation/University of Pavia, Pavia, Pavia, Italy

    Background/Purpose: Drug-free (DF) remission, as a putative proxy of cure, has recently gained the attention of the scientific community as a desirable new target of…
  • Abstract Number: 2116 • ACR Convergence 2022

    Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis

    Juan Josè de Agustin1, Gustavo Añez1, delia reina2, Sergi Heredia3, Felipe Julio Ramirez Garcia4, Andrea Cuervo5, Jesus Rodriguez6, Carmen Moragues6, Patricia Moya7, Mireia Moreno8, Marta Arévalo8, Manel Pujol9, Georgina Salvador9, Noemi Busquets10, andres Ponce10, Ana Maria Laiz Alonso7 and MAria Pascual Pastor11, 1Vall D'hebron University Hospital, Barcelona, Spain, 2Complex Hospitalari Moisès Broggi, Sant Joan Despí, Catalonia, Spain, 3Complex Hospitalari Moisès Broggi, Sant Joan Despi, Catalonia, Spain, 4Hospital Clínic, Barcelona, Spain, 5Hospital Clínico y Provincial de Barcelona, Barcelona, Spain, 6Hospital Bellvitge, Hospitalet de Llobregat, Spain, 7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 8Parc Tauli Hospital Universitari, Sabadell, Catalonia, Spain, 9Hospital Universitario MútuaTerrassa, Terrassa, Spain, 10Hospital General de Granollers, Granollers, Spain, 11Hospital Universitari Vall d'Hebron, Barcelona, Spain

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease involving joint and enthesis disease. Ultrasound (US) has demonstrated its useful tool for the diagnosis of…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology